Revvity Prazosin, -, 250µci (9.25mbq)

Revvity 250 µCi quantities of Prazosin, [7-Methoxy-³H]-, are available for your research. Prazosin is an α1-blocker, and is used to treat high blood pressure, anxiety, and post-traumatic stress disorder. It binds the α1-adrenergic receptor, a GPCR that plays a role in vasconstriction and appetite suppression. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (B_max), dissociation constants (K_d), association and dissociation rates (k_on and k_off), and inhibitor constants (K_i) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity References for NET823: - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Oshita, M., Kigoshi, S. and Muramatsu, I. (1991), Three distinct binding sites for [3H]-prazosin in the rat cerebral cortex. British Journal of Pharmacology, 104: 961–965.Hanft, g., Gross, g., Beckeringh, J. J. and Korstanje, C. (1989), α1-Adrenoceptors: the ability of various agonists and antagonists to discriminate between two distinct [3H]prazosin binding sites. Journal of Pharmacy and Pharmacology, 41: 714–716.